DoW Breast Cancer, Clinical Research Extension Award
Defense Health Agency Contracting Activity - DHACA
Free. Verify your email, then we send one reminder only.
- Posted
- Aug 20, 2026
- Closes
- Nov 18, 2026 (in 75 days)
Similar opportunities open now
- DoW Breast Cancer, Breakthrough Award Levels 1 and 2Same funderOpenDefense Health Agency Contracting Activity - DHACACloses in 75 days
- DoW Rare Cancers Resource and Community Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 75 days
- DoW Rare Cancers Concept AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 26 days
- DoW Duchenne Muscular Dystrophy, Clinical/Translational Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 14 days
- DoW Kidney Cancer, Idea Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 24 days
Classification and identifiers
- Solicitation number
- HT942526BCRPCREA2
- Assistance listing (CFDA)
- 12.420
Amount
Amount not published by the funder
Who can apply
About this opportunity
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical studies by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Distinctive Features: • The research team must include two or more breast cancer consumer advocates. • This funding mechanism allows for a single Principal In...